The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
On May 18, a U.S. jury found Takeda Pharmaceutical liable for approximately $885 million in damages for delaying a generic version of its drug Amitiza. This ruling is part of an antitrust case focusing on Takeda's market practices.